Aerie pharmaceuticals receives european commission approval for rhokiinsa® (netarsudil ophthalmic solution) 0.02%

Aerie pharmaceuticals, inc. announced the european commission (ec) has granted a marketing authorisation for rhokiinsa® (netarsudil ophthalmic solution) 0.02% for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension.the marketing authorisation application (maa) for rhokiinsa® was accepted for review by the european medicines agency (ema) in october 2018. aerie received a positive scientific opinion recommending approval of the rhokiinsa® maa from the ema’s committee for medicinal products for human use (chmp) in september 2019. rhokiinsa® was approved by the u.s. food and drug administration (fda) in december 2017 under the trade name rhopressa® for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. roclanda® was approved by the fda in march 2017 under the trade name rocklatan® for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
AERI Ratings Summary
AERI Quant Ranking